Lenalidomide bypasses CD28 co-stimulation to reinstate PD-1 immunotherapy by activating Notch signaling

An, 2017, pSILAC mass spectrometry reveals ZFP91 as IMiD-dependent substrate of the CRL4(CRBN) ubiquitin ligase, Nat. Commun., 8, 15398, 10.1038/ncomms15398 Aue, 2018, Activation of Th1 immunity within the tumor microenvironment is associated with clinical response to lenalidomide in chronic lymphocytic leukemia, J. Immunol., 201, 1967, 10.4049/jimmunol.1800570 Bandyopadhyay, 2007, Interleukin 2 gene transcription is regulated by Ikaros-induced changes in histone acetylation in anergic T cells, Blood, 109, 2878, 10.1182/blood-2006-07-037754 Bartlett, 2004, The evolution of thalidomide and its IMiD derivatives as anticancer agents, Nat. Rev. Cancer, 4, 314, 10.1038/nrc1323 Berg, 2011, Safety, pharmacokinetics, and immunomodulatory effects of lenalidomide in children and adolescents with relapsed/refractory solid tumors or myelodysplastic syndrome: a Children's Oncology Group Phase I Consortium report, J. Clin. Oncol., 29, 316, 10.1200/JCO.2010.30.8387 Besson, 2018, One-year follow-up of natural killer cell activity in multiple myeloma patients treated with adjuvant lenalidomide therapy, Front. Immunol., 9, 704, 10.3389/fimmu.2018.00704 Boon, 1994, Tumor antigens recognized by T lymphocytes, Annu. Rev. Immunol., 12, 337, 10.1146/annurev.iy.12.040194.002005 Chamberlain, 2014, Structure of the human Cereblon-DDB1-lenalidomide complex reveals basis for responsiveness to thalidomide analogs, Nat. Struct. Mol. Biol., 21, 803, 10.1038/nsmb.2874 Chanan-Khan, 2017, Lenalidomide maintenance therapy in previously treated chronic lymphocytic leukaemia (CONTINUUM): a randomised, double-blind, placebo-controlled, phase 3 trial, Lancet Haematol., 4, e534, 10.1016/S2352-3026(17)30168-0 Chen, 2013, Oncology meets immunology: the cancer-immunity cycle, Immunity, 39, 1, 10.1016/j.immuni.2013.07.012 Cheng, 2021, Bone marrow mesenchymal stem cells promote prostate cancer cell stemness via cell-cell contact to activate the Jagged1/Notch1 pathway, Cell Biosci., 11, 87, 10.1186/s13578-021-00599-0 Dahut, 2009, Phase I study of oral lenalidomide in patients with refractory metastatic cancer, J. Clin. Pharmacol., 49, 650, 10.1177/0091270009335001 Di, 2020, Phenotype molding of T cells in colorectal cancer by single-cell analysis, Int. J. Cancer, 146, 2281, 10.1002/ijc.32856 Dunn, 2004, The three Es of cancer immunoediting, Annu. Rev. Immunol., 22, 329, 10.1146/annurev.immunol.22.012703.104803 Esensten, 2016, CD28 costimulation: from mechanism to therapy, Immunity, 44, 973, 10.1016/j.immuni.2016.04.020 Filaci, 2007, CD8+ CD28- T regulatory lymphocytes inhibiting T cell proliferative and cytotoxic functions infiltrate human cancers, J. Immunol., 179, 4323, 10.4049/jimmunol.179.7.4323 Fink, 2017, Lenalidomide maintenance after first-line therapy for high-risk chronic lymphocytic leukaemia (CLLM1): final results from a randomised, double-blind, phase 3 study, Lancet Haematol., 4, e475, 10.1016/S2352-3026(17)30171-0 Fink, 2018, Crbn (I391V) is sufficient to confer in vivo sensitivity to thalidomide and its derivatives in mice, Blood, 132, 1535, 10.1182/blood-2018-05-852798 Gandhi, 2014, Immunomodulatory agents lenalidomide and pomalidomide co-stimulate T cells by inducing degradation of T cell repressors Ikaros and Aiolos via modulation of the E3 ubiquitin ligase complex CRL4CRBN, Br. J. Haematol., 164, 811, 10.1111/bjh.12708 Gao, 2020, Novel immunomodulatory drugs and neo-substrates, Biomark. Res., 8, 2, 10.1186/s40364-020-0182-y Geimer Le Lay, 2014, The tumor suppressor Ikaros shapes the repertoire of notch target genes in T cells, Sci. Signal., 7, ra28, 10.1126/scisignal.2004545 Gemechu, 2018, Humanized cereblon mice revealed two distinct therapeutic pathways of immunomodulatory drugs, Proc. Natl. Acad. Sci. U S A, 115, 11802, 10.1073/pnas.1814446115 Görgün, 2015, Lenalidomide enhances immune checkpoint blockade-induced immune response in multiple myeloma, Clin. Cancer Res., 21, 4607, 10.1158/1078-0432.CCR-15-0200 Hagner, 2015, CC-122, a pleiotropic pathway modifier, mimics an interferon response and has antitumor activity in DLBCL, Blood, 126, 779, 10.1182/blood-2015-02-628669 Haslett, 1998, Thalidomide costimulates primary human T lymphocytes, preferentially inducing proliferation, cytokine production, and cytotoxic responses in the CD8+ subset, J. Exp. Med., 187, 1885, 10.1084/jem.187.11.1885 Hui, 2017, T cell costimulatory receptor CD28 is a primary target for PD-1-mediated inhibition, Science, 355, 1428, 10.1126/science.aaf1292 Ioannou, 2021, Triggering interferon signaling in T cells with avadomide sensitizes CLL to anti-PD-L1/PD-1 immunotherapy, Blood, 137, 216, 10.1182/blood.2020006073 Jenkins, 1988, Allogeneic non-T spleen cells restore the responsiveness of normal T cell clones stimulated with antigen and chemically modified antigen-presenting cells, J. Immunol., 140, 3324, 10.4049/jimmunol.140.10.3324 Kakuda, 2020, Canonical Notch ligands and Fringes have distinct effects on NOTCH1 and NOTCH2, J. Biol. Chem., 295, 14710, 10.1074/jbc.RA120.014407 Kamphorst, 2017, Rescue of exhausted CD8 T cells by PD-1-targeted therapies is CD28-dependent, Science, 355, 1423, 10.1126/science.aaf0683 Kim, 2020, PD-1 blockade-unresponsive human tumor-infiltrating CD8(+) T cells are marked by loss of CD28 expression and rescued by IL-15, Cell. Mol. Immunol., 18, 385, 10.1038/s41423-020-0427-6 Krämer, 2016, Lenalidomide enhances myeloma-specific T-cell responses in vivo and in vitro, OncoImmunology, 5, e1139662, 10.1080/2162402X.2016.1139662 Kronke, 2015, Lenalidomide induces ubiquitination and degradation of CK1α in del(5q) MDS., Nature, 523, 183, 10.1038/nature14610 Krönke, 2014, Lenalidomide causes selective degradation of IKZF1 and IKZF3 in multiple myeloma cells, Science, 343, 301, 10.1126/science.1244851 Kuai, 2017, Designer vaccine nanodiscs for personalized cancer immunotherapy, Nat. Mater., 16, 489, 10.1038/nmat4822 Lagrue, 2015, Lenalidomide augments actin remodeling and lowers NK-cell activation thresholds, Blood, 126, 50, 10.1182/blood-2015-01-625004 Laky, 2015, Notch signaling regulates antigen sensitivity of naive CD4+ T cells by tuning co-stimulation, Immunity, 42, 80, 10.1016/j.immuni.2014.12.027 Lapenta, 2019, Lenalidomide improves the therapeutic effect of an interferon-alpha-dendritic cell-based lymphoma vaccine, Cancer Immunol. Immunother., 68, 1791, 10.1007/s00262-019-02411-y LeBlanc, 2004, Immunomodulatory drug costimulates T cells via the B7-CD28 pathway, Blood, 103, 1787, 10.1182/blood-2003-02-0361 Lu, 2014, The myeloma drug lenalidomide promotes the cereblon-dependent destruction of Ikaros proteins, Science, 343, 305, 10.1126/science.1244917 Matyskiela, 2016, A novel cereblon modulator recruits GSPT1 to the CRL4CRBN ubiquitin ligase, Nature, 535, 252, 10.1038/nature18611 Matyskiela, 2018, A cereblon modulator (CC-220) with improved degradation of Ikaros and aiolos, J. Med. Chem., 61, 535, 10.1021/acs.jmedchem.6b01921 Ménard, 2021, Lenalidomide triggers T-cell effector functions in vivo in patients with follicular lymphoma, Blood Adv., 5, 2063, 10.1182/bloodadvances.2020003774 Miller, 2007, Phase I study of lenalidomide in solid tumors, J. Thorac. Oncol., 2, 445, 10.1097/01.JTO.0000268679.33238.67 Mitra, 2020, CD28 signaling drives notch ligand expression on CD4 T cells, Front. Immunol., 11, 735, 10.3389/fimmu.2020.00735 Palma, 2018, Lenalidomide as immune adjuvant to a dendritic cell vaccine in chronic lymphocytic leukemia patients, Eur. J. Haematol., 101, 68, 10.1111/ejh.13065 Paolini, 2021, Mechanosensitive Notch-Dll4 and Klf2-Wnt9 signaling pathways intersect in guiding valvulogenesis in zebrafish, Cell Rep., 37, 109782, 10.1016/j.celrep.2021.109782 Powell, 1998, Molecular regulation of interleukin-2 expression by CD28 co-stimulation and anergy, Immunol. Rev., 165, 287, 10.1111/j.1600-065X.1998.tb01246.x Quintana, 2012, Aiolos promotes TH17 differentiation by directly silencing Il2 expression, Nat. Immunol., 13, 770, 10.1038/ni.2363 Semeraro, 2013, Trial watch: lenalidomide-based immunochemotherapy, OncoImmunology, 2, e26494, 10.4161/onci.26494 Subramanian, 2005, Gene set enrichment analysis: a knowledge-based approach for interpreting genome-wide expression profiles, Proc. Natl. Acad. Sci. U S A, 102, 15545, 10.1073/pnas.0506580102 Surka, 2020, CC-90009, a novel cereblon E3 ligase modulator targets acute myeloid leukemia blasts and leukemia stem cells, Blood, 137, 661, 10.1182/blood.2020008676 Tchekneva, 2019, Determinant roles of dendritic cell-expressed Notch Delta-like and Jagged ligands on anti-tumor T cell immunity, J. Immunother. Cancer, 7, 95, 10.1186/s40425-019-0566-4 Wang, 2018, Lenalidomide enhances the function of CS1 chimeric antigen receptor-redirected T cells against multiple myeloma, Clin. Cancer Res., 24, 106, 10.1158/1078-0432.CCR-17-0344 Warren, 2011, Phase I trial of lenalidomide in pediatric patients with recurrent, refractory, or progressive primary CNS tumors: pediatric Brain Tumor Consortium study PBTC-018, J. Clin. Oncol., 29, 324, 10.1200/JCO.2010.31.3601 Weng, 2009, CD28(-) T cells: their role in the age-associated decline of immune function, Trends Immunol., 30, 306, 10.1016/j.it.2009.03.013 Witzig, 2015, A comprehensive review of lenalidomide therapy for B-cell non-Hodgkin lymphoma, Ann. Oncol., 26, 1667, 10.1093/annonc/mdv102